Company intelligence / Profile preview

Sunshine Biopharma Inc.

Fort Lauderdale, Florida, United Statessunshinebiopharma.com ↗

Ownership: Public · SBFM
Employees: ~44
Development stage: Preclinical

Overview

The company has approximately 70 generic prescription drugs on the market in Canada while developing proprietary candidates including K1.1 mRNA for liver cancer, Adva-27a for pancreatic cancer, and PLpro inhibitors for COVID-19.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculesmRNA
Industry: Biotech

Drug pipeline

8 assets

K1.1

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

University of ArizonaUniversity of Illinois Chicago

Financials

Market cap: $2.7M
Total revenue: $9.3M
Enterprise value: $-10.4M

Beyond the preview

Go deeper on Sunshine Biopharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sunshine Biopharma Inc..

Explore the full profile